Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS:TLFTF) said Wednesday that it is teaming up with Dr Don Garbuz, an orthopedic surgeon, to study the effectiveness of the company’s Canntab tablets in reducing the need for opioids after knee-replacement surgery.
The Toronto-based company said in a press release that it’s seeking approval from the university to conduct a randomized, double-blind, placebo-controlled clinical trial, with Garbuz as lead investigator.
Shares of Canntab climbed C$0.07 to C$1.12 in Wednesday’s Canadian trading.
Garbuz is head of the division of lower limb reconstruction and oncology at the University of British Columbia’s division of orthopedics.
Canntab plans to create the tablets for the study with Toronto-based FSD Pharma Inc (OTCMKTS:FSDDF), a licensed producer under the Access to Cannabis for Medical Purposes Regulations.
“This study will help advance our understanding of